Pharmaceuticals, Biotechnology & Life Sciences

Satellos Bioscience: pioneering muscle‑regeneration therapies in Canada, boosting healing for severe muscle disorders with cutting‑edge biotech innovations.

European Commission approves Wegovy tablet; Novo Nordisk sees strong investor lift and positive long‑term data on hemophilia candidate Denecimig.

Pharmaron boosts its CDMO outlook, driving 10% profit growth and a 6.8% margin, as demand for contract drug development surges in a rebounding healthcare market.

Explore Hefei Lifeon Pharmaceutical’s solid mid‑cap profile, diversified drug lineup, and growing investor interest amid China’s healthcare reforms.

Orexo AB’s Q2 2026 results show a deepening loss but a hopeful clinical roadmap—key FDA milestones could turn debt‑heavy biotech into a growth story.

Unicycive Therapeutics leads the fight against hyperphosphatemia in kidney disease with two breakthrough therapies, offering safer, more effective options for patients and investors alike.

Explore Anavex Life Sciences’ breakthrough in precision genetic medicine targeting rare neurological disorders and its growth potential in the biotech market.

Discover why Agenus Inc. stock jumped 100% after a $340M private placement, funding the high‑potential BOT + BAL Phase 3 trial for MSS colon cancer and sparking a $30 analyst target.

AbbVie’s July 2026 ex‑dividend and Skyrizi‑driven $300 target show a resilient dividend strategy amid a brief price dip, yet drug‑pricing policy shifts still shape future gains.

Discover how aTyr Pharma’s physiocrine‑based biotech innovations could transform healthcare, plus insights into its market performance and future prospects.